Alliqua, a developer of transdermal wound care and drug delivery technologies, has appointed Stephen Brigido as the company's new chairman for scientific advisory board (SAB).
Previously, Brigido served as chairman of Institutional Review Board of Coordinated Health for foot and ankle surgery.
Alliqua president Richard Rosenblum said Brigido is keenly aware of the demands on wound care products and the role for transdermal applications for drug delivery.
"His experience as well as his professional reputation will be invaluable to us as we further our SilverSeal commercialization plans," Brigido added.
" Additionally, as chairman, we are confident that he will play an active role in helping to steer our future development plans and product road map to maximize our growth potential in the coming years."
Alliqua chairman Stephen Brigido said having had direct experience with the company’s SilverSeal, silver based, hydrogel wound dressings, he believe the application, along with company’s technology platform, has good commercial potential in the areas of wound care and the transdermal delivery of a wide array of drugs.
"I look forward to working with the scientific and business team at Alliqua to help drive the development of Alliqua’s products and deliver on this company’s vast potential to help patients suffering from lower extremity wounds," Brigido added.